Summit Therapeutics IncNASDAQ:SMMT
- LAST PRICE4.4500
- TODAY'S CHANGE (%)-0.0600 (-1.3304%)
- Bid / Lots4.4500/ 6
- Ask / Lots4.4600/ 17
- Open / Previous Close4.5400 / 4.5100
- Day Range
- 52 Week Range
- Volume561,260
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SMMT |
|---|---|---|
| 09:32 ET | 38985 | 4.52 |
| 09:34 ET | 4040 | 4.52 |
| 09:36 ET | 17196 | 4.44 |
| 09:38 ET | 2541 | 4.45 |
| 09:39 ET | 400 | 4.45 |
| 09:41 ET | 1348 | 4.5 |
| 09:43 ET | 300 | 4.5 |
| 09:45 ET | 430 | 4.52 |
| 09:48 ET | 1020 | 4.53 |
| 09:50 ET | 300 | 4.53 |
| 09:52 ET | 11227 | 4.565 |
| 09:54 ET | 4064 | 4.54 |
| 09:56 ET | 480 | 4.54 |
| 09:57 ET | 1000 | 4.5401 |
| 09:59 ET | 3144 | 4.55 |
| 10:01 ET | 2222 | 4.565 |
| 10:03 ET | 11937 | 4.565 |
| 10:06 ET | 471 | 4.565 |
| 10:08 ET | 8093 | 4.58 |
| 10:10 ET | 2686 | 4.575 |
| 10:12 ET | 1930 | 4.56 |
| 10:14 ET | 100 | 4.555 |
| 10:15 ET | 300 | 4.555 |
| 10:19 ET | 100 | 4.555 |
| 10:21 ET | 7258 | 4.59 |
| 10:24 ET | 200 | 4.595 |
| 10:26 ET | 3710 | 4.615 |
| 10:28 ET | 4367 | 4.625 |
| 10:30 ET | 7732 | 4.615 |
| 10:32 ET | 13694 | 4.575 |
| 10:33 ET | 1500 | 4.575 |
| 10:35 ET | 1440 | 4.575 |
| 10:37 ET | 6590 | 4.5725 |
| 10:39 ET | 9384 | 4.545 |
| 10:42 ET | 5109 | 4.5217 |
| 10:44 ET | 2415 | 4.525 |
| 10:46 ET | 650 | 4.525 |
| 10:48 ET | 400 | 4.53 |
| 10:50 ET | 1257 | 4.515 |
| 10:51 ET | 3775 | 4.49 |
| 10:53 ET | 900 | 4.49 |
| 10:55 ET | 8811 | 4.5 |
| 10:57 ET | 2168 | 4.49 |
| 11:00 ET | 4126 | 4.54 |
| 11:02 ET | 2128 | 4.53 |
| 11:04 ET | 300 | 4.525 |
| 11:06 ET | 2000 | 4.525 |
| 11:08 ET | 3480 | 4.515 |
| 11:09 ET | 700 | 4.51 |
| 11:11 ET | 4100 | 4.515 |
| 11:13 ET | 8641 | 4.505 |
| 11:15 ET | 2870 | 4.535 |
| 11:18 ET | 300 | 4.535 |
| 11:20 ET | 417 | 4.535 |
| 11:22 ET | 600 | 4.535 |
| 11:24 ET | 1202 | 4.535 |
| 11:26 ET | 1050 | 4.535 |
| 11:27 ET | 3919 | 4.535 |
| 11:29 ET | 100 | 4.535 |
| 11:31 ET | 1466 | 4.555 |
| 11:33 ET | 600 | 4.555 |
| 11:36 ET | 2674 | 4.555 |
| 11:38 ET | 1150 | 4.558 |
| 11:40 ET | 3457 | 4.55 |
| 11:42 ET | 4784 | 4.525 |
| 11:44 ET | 2000 | 4.515 |
| 11:45 ET | 600 | 4.515 |
| 11:47 ET | 14660 | 4.525 |
| 11:49 ET | 280 | 4.525 |
| 11:51 ET | 200 | 4.525 |
| 11:54 ET | 2963 | 4.535 |
| 11:56 ET | 300 | 4.53 |
| 11:58 ET | 617 | 4.53 |
| 12:00 ET | 650 | 4.5357 |
| 12:02 ET | 2652 | 4.545 |
| 12:03 ET | 500 | 4.545 |
| 12:05 ET | 1631 | 4.545 |
| 12:07 ET | 9319 | 4.525 |
| 12:09 ET | 1528 | 4.53 |
| 12:12 ET | 3811 | 4.52 |
| 12:14 ET | 8858 | 4.505 |
| 12:16 ET | 232 | 4.505 |
| 12:18 ET | 300 | 4.5 |
| 12:20 ET | 1400 | 4.505 |
| 12:21 ET | 4688 | 4.48 |
| 12:23 ET | 500 | 4.485 |
| 12:25 ET | 4031 | 4.495 |
| 12:27 ET | 2865 | 4.485 |
| 12:30 ET | 400 | 4.485 |
| 12:34 ET | 2421 | 4.485 |
| 12:36 ET | 7532 | 4.485 |
| 12:38 ET | 550 | 4.4884 |
| 12:39 ET | 200 | 4.48 |
| 12:41 ET | 100 | 4.48 |
| 12:43 ET | 44480 | 4.46 |
| 12:45 ET | 1100 | 4.465 |
| 12:48 ET | 200 | 4.46 |
| 12:50 ET | 9838 | 4.455 |
| 12:52 ET | 3875 | 4.46 |
| 12:54 ET | 1729 | 4.455 |
| 12:56 ET | 300 | 4.45 |
| 12:57 ET | 1200 | 4.45 |
| 12:59 ET | 100 | 4.455 |
| 01:01 ET | 3905 | 4.435 |
| 01:03 ET | 5579 | 4.45 |
| 01:06 ET | 2704 | 4.455 |
| 01:08 ET | 4594 | 4.44 |
| 01:10 ET | 2050 | 4.44 |
| 01:12 ET | 2126 | 4.455 |
| 01:15 ET | 1740 | 4.45 |
| 01:17 ET | 700 | 4.455 |
| 01:19 ET | 625 | 4.45 |
| 01:24 ET | 1533 | 4.4499 |
| 01:26 ET | 200 | 4.45 |
| 01:28 ET | 3021 | 4.46 |
| 01:30 ET | 417 | 4.475 |
| 01:32 ET | 300 | 4.475 |
| 01:33 ET | 1594 | 4.47 |
| 01:37 ET | 100 | 4.47 |
| 01:39 ET | 1967 | 4.485 |
| 01:42 ET | 831 | 4.485 |
| 01:44 ET | 8229 | 4.495 |
| 01:46 ET | 1200 | 4.495 |
| 01:50 ET | 3309 | 4.49 |
| 01:51 ET | 100 | 4.49 |
| 01:53 ET | 200 | 4.49 |
| 01:55 ET | 700 | 4.48 |
| 02:00 ET | 2300 | 4.48 |
| 02:02 ET | 200 | 4.48 |
| 02:04 ET | 8731 | 4.47 |
| 02:06 ET | 200 | 4.47 |
| 02:08 ET | 2077 | 4.475 |
| 02:09 ET | 100 | 4.47 |
| 02:11 ET | 300 | 4.4711 |
| 02:13 ET | 2350 | 4.46 |
| 02:15 ET | 100 | 4.46 |
| 02:18 ET | 2703 | 4.465 |
| 02:20 ET | 100 | 4.46 |
| 02:24 ET | 5325 | 4.455 |
| 02:26 ET | 100 | 4.46 |
| 02:27 ET | 4731 | 4.46 |
| 02:29 ET | 100 | 4.465 |
| 02:31 ET | 1789 | 4.46 |
| 02:33 ET | 4684 | 4.46 |
| 02:36 ET | 2388 | 4.47 |
| 02:38 ET | 100 | 4.465 |
| 02:40 ET | 459 | 4.46 |
| 02:42 ET | 100 | 4.46 |
| 02:44 ET | 1626 | 4.46 |
| 02:45 ET | 226 | 4.45 |
May 7, 2024
DJ Summit Therapeutics Initiated at Buy by Citigroup, from 8:27AM ET on Tuesday May 07, 2024 by Dow Jones
8:27AM ET on Tuesday May 07, 2024 by Dow Jones
May 1, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024, from 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
7:00AM ET on Wednesday May 01, 2024 by Dow Jones*DJ Summit Therapeutics 1Q Loss/Shr 6c >SMMT, from 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
7:00AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 24, 2024
Press Release: Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024, from 4:46PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:46PM ET on Wednesday Apr 24, 2024 by Dow JonesSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024, from 4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Summit Therapeutics Inc | 3.2B | -2.9x | --- |
Apogee Therapeutics Inc | 3.1B | -29.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.6x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.1x | --- |
SpringWorks Therapeutics Inc | 3.3B | -8.6x | --- |
Company Information
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Contact Information
- Headquarters
- 2882 Sand Hill Road, Suite 106MENLO PARK, CA, United States 94025
- Phone
- 650-460-8308
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Chief Executive Officer
- Robert Duggan
- President, Co-Chief Executive Officer, Director
- Mahkam Zanganeh
- Chief Financial Officer
- Ankur Dhingra
- Chief Operating Officer, Director
- Manmeet Soni
- Lead Non-Executive Independent Director
- Kenneth Clark
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
